U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06894628) titled 'Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation' on March 18.
Brief Summary: The study aims to validate the Decipher(R) genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction).
Validating the Decipher(R) genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"
Study Start Date: Nov. 04, 2024
Study Type: OBSERVATIONAL
Condition:
Prostatic Neoplasms
Recruitment Status: RECRUITING
Sponsor: Regina Elena Cancer Institute
Disclai...